Photo by nci from unsplash
In the phase II FIGHT trial, adding bemarituzumab to chemotherapy led to longer progression-free survival and overall survival in patients with advanced FGFR2b-positive gastric or gastroesophageal junction cancers. However, the… Click to show full abstract
In the phase II FIGHT trial, adding bemarituzumab to chemotherapy led to longer progression-free survival and overall survival in patients with advanced FGFR2b-positive gastric or gastroesophageal junction cancers. However, the agent was also associated with more side effects, including eye problems.
Keywords:
inhibitor stymies;
fgfr inhibitor;
cancer;
gastric cancer;
stymies gastric
Journal Title: Cancer discovery
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!